RxDoctor Payments Data

Merete Vogelsong

Nurse Practitioner · Williamsport, PANPI 1033691126

Payments from drug & device makers

$4,680in general payments, 2019–2025

Across 76 payments — averaging $61.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Edwards Lifesciences$809
  • Johnson & Johnson$457
  • Boehringer Ingelheim$268
  • E.r. Squibb & Sons, L.L.C.$231
  • GSK$223
  • plus $2K from 16 others

What the payments were for

  • Travel & lodging$321%
  • Food & beverage$4,51697%
  • Education$1313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,680 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,906
Medicare patients
363
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban322$327,349
EntrestoSacubitril/Valsartan147$134,463
Repatha SureclickEvolocumab93$67,558
JardianceEmpagliflozin74$65,539
XareltoRivaroxaban46$41,425
BrilintaTicagrelor37$20,013
FarxigaDapagliflozin Propanediol23$16,247
Metoprolol Succinate889$11,152
Rosuvastatin Calcium351$5,284
Atorvastatin Calcium357$4,491
Ezetimibe157$3,376
Ranolazine ErRanolazine33$3,117
Valsartan21$2,803
ClopidogrelClopidogrel Bisulfate152$1,739
Dofetilide12$1,705

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$160$327,349322 claims
NovartisEntresto$26$134,463147 claims
Boehringer IngelheimJardiance$268$65,53974 claims
Johnson & JohnsonXarelto$457$41,42546 claims
AstraZenecaBrilinta, Farxiga$217$36,26160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Williamsport

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →